Skip to main content

Table 2 Tumor maximum width average measures

From: Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging

 

HRCVTMR

HRCTVTRUS

Obs. 1

Obs. 2

Obs. 1

Obs. 2

Obs. 1

Obs. 2

All stages

45.2 ± 12.7

43.6 ± 12.6

43.7 ± 12.2

43.9 ± 11.4

42.5 ± 11.9

43 ± 11.2

FIGO I

37.4 ± 7.7

37.4 ± 9.2

36.1 ± 8.8

36.3 ± 7.3

36.9 ± 8.7

36.5 ± 8.4

FIGO II

41.6 ± 8.4

39.7 ± 7.9

40.4 ± 7.9

40.6 ± 7.3

39.2 ± 8

39.6 ± 6.8

FIGO III

60.2 ± 11.3

58.2 ± 12.4

58.1 ± 11.7

57.9 ± 10.1

54.7 ± 12.9

57 ± 10.7

FIGO IV

63.7 ± 11.7

61.5 ± 11.2

60.1 ± 11.8

61.2 ± 9.4

58.3 ± 12.5

57.9 ± 11.2

  1. Tumor maximum width average measures in mm (± standard deviations) measured in PreBT MR imaging (HRCTVMR) and in PreBT TRUS imaging acquired at the time of first brachytherapy application with no applicator in place (HRCTVTRUS), presented by FIGO (International Federation of Gynaecology and Obstetrics) stages. (Abbreviations: Obs. Observer)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us